Published in J Urol on November 01, 1998
A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer (2011) 1.17
Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology (2008) 0.99
BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One (2013) 0.90
Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges. J Korean Med Sci (2015) 0.77
Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history. Prostate Cancer Prostatic Dis (2008) 0.77
Towards a better crystal ball. J Urol (1998) 0.75
Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions. Med J Armed Forces India (2011) 0.75
Usefulness of Total PSA Value in Prostate Diseases Diagnosis. Acta Inform Med (2016) 0.75
Re: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol (1999) 0.75
Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. Rev Urol (2003) 0.75
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
The impact of course attendance on the practice of dentists. Br Dent J (2004) 2.08
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol (1999) 2.07
Assessment in postgraduate dental education: an evaluation of strengths and weaknesses. Med Educ (2001) 2.07
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet (2001) 2.03
Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA (1996) 1.97
A method for dinitrochlorobenzene contact sensitization. A clinicopathological study. N Engl J Med (1972) 1.88
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol (1994) 1.81
Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA (2001) 1.71
Clinical use of prostate specific antigen in patients with prostate cancer. J Urol (1989) 1.71
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol (1996) 1.70
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol (2000) 1.69
Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion (1995) 1.59
Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet (2000) 1.57
Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in radical prostatectomy. Anesth Analg (1997) 1.56
Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med (2001) 1.55
Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend (1996) 1.54
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol (2000) 1.50
Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study analysis of efficacy. Anesth Analg (1994) 1.42
A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology (1999) 1.41
Expectant management and the natural history of localized prostate cancer. J Urol (1994) 1.38
Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection. J Urol (1991) 1.38
Radical surgery for advanced prostate cancer and for radiation failures. J Urol (1992) 1.38
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol (2001) 1.37
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol (2000) 1.36
Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin (2001) 1.35
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer (2000) 1.34
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer (2000) 1.34
Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage. Cancer (1973) 1.33
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol (1987) 1.33
Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther (2007) 1.25
The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer (1997) 1.25
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24
Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol (1985) 1.24
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology (1993) 1.23
Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu (1990) 1.22
Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer (1980) 1.22
Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology (1995) 1.22
Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients. Surg Gynecol Obstet (1973) 1.21
Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol (1994) 1.19
Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes. Clin Exp Immunol (1975) 1.17
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology (1999) 1.16
The nature of prostate cancer detected through prostate specific antigen based screening. J Urol (1994) 1.16
Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology. Cancer (1973) 1.16
Quantitative dinitrochlorobenzene contact sensitization in a normal population. Clin Exp Immunol (1972) 1.15
Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res (2001) 1.13
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology (1996) 1.12
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol (1997) 1.12
Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol (1987) 1.10
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol (1994) 1.10
Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology (2000) 1.10
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol (1998) 1.09
Xanthogranulomatous pyelonephritis masquerading as occult malignancy. Urology (1978) 1.08
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res (2000) 1.06
Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol (1987) 1.04
Subtypes of adult antisocial behavior among drug abusers. J Nerv Ment Dis (1995) 1.04
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol (1997) 1.04
gamma-Interferon induced by S. aureus protein A augments natural killing and ADCC. Nature (1981) 1.00
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer Prostatic Dis (2006) 1.00
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol (1997) 0.99
Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer (2000) 0.99
Proceedings: Cellular immunity in cured cancer patients. Cancer (1974) 0.99
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol (1994) 0.99
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther (2012) 0.98
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol (1982) 0.97
Self-report stability for substance use over 10 years: data from the St. Louis Epidemiologic Catchment Study. Drug Alcohol Depend (1995) 0.97
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol (1999) 0.97
Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology (1997) 0.97
Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res (1984) 0.96
Interferon induction and augmentation of natural-killer activity by Staphylococcus protein A. Cell Immunol (1981) 0.95
Production of macrophage activation factor by a T-cell hybridoma. Cell Immunol (1982) 0.95
Replication linkage study for prostate cancer susceptibility genes. Prostate (2000) 0.95
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol (1986) 0.94
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol (2001) 0.94
Network-based approaches in drug discovery and early development. Clin Pharmacol Ther (2013) 0.94
Occurrence of hernia of Morgagni with filial cervical lung hernia: a hereditary defect of the cervical mesenchyme? Chest (1972) 0.93
Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol (1988) 0.93
Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol (1994) 0.93
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol (1996) 0.93
An isolated plexiform neurofibroma of the bladder. J Urol (1985) 0.93
High resolution sonography in diagnosing testicular neoplasms: clinical significance of false positive scans. J Urol (1986) 0.92
Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology (1998) 0.92
Emphysematous pyelonephritis: successful management by percutaneous drainage. J Urol (1986) 0.92
Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol (1992) 0.92
Testicular microlithiasis: US follow-up. Radiology (2001) 0.91